Catalyst Pharmaceuticals
Open
$31.37
Prev. Close
$31.37
High
$31.38
Low
$31.36
Market Snapshot
$3.83B
17.3
1.38
$491.73M
182
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 182 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 182 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Recently from Cashu
Catalyst Pharmaceuticals Secures Legal Win, Ensures FIRDAPSE Market Exclusivity Until 2035
Catalyst Pharmaceuticals (Ticker: CPRX) achieves a critical legal victory in its ongoing efforts to protect its commercial interests, particularly concerning its lead product, FIRDAPSE. The company ha…
Catalyst Pharmaceuticals Drives Revenue Growth with Innovative Product Launch and International Expansion
Catalyst Pharmaceuticals Champions Innovative Product Launch for Revenue Growth Catalyst Pharmaceuticals demonstrates remarkable resilience and innovation as it unveils a new product line that drives…
Catalyst Pharmaceuticals Reports Strong Q4 Growth Driven by Firdapse Demand and R&D Expansion
Catalyst Pharmaceuticals Highlights Strong Growth in Q4 Earnings Report Catalyst Pharmaceuticals, a key player in the biopharmaceutical industry, recently unveils its fourth-quarter earnings report, s…
Catalyst Pharmaceuticals Reports Strong Growth in LEMS Treatment and Future Innovations
Catalyst Pharmaceuticals Focuses on Growth in LEMS Treatment Catalyst Pharmaceuticals, a key player in the biotechnology sector known for its commitment to rare disease therapies, releases its Q4 earn…